Search

everythinglearnresearchcommunity

for

Search:↓

Topical Minoxidil may cause pericardial effusion. Caution is advised when using Minoxidil, even topically.

A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.

Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

An 18-year-old male with hair loss is considering starting finasteride but is concerned about potential side effects like gynecomastia due to his prolactin levels. He seeks guidance on whether his bloodwork indicates it's safe to begin treatment.

Hair loss treatments and whether or not to buy pyrilutamide, with some users recommending using RU58841, Minoxidil, and finasteride.

The conversation discusses using Bimatoprost for eyebrow regrowth and its potential use on the hairline, with concerns about cost and side effects. Alternatives like topical Minoxidil are mentioned, but the user is worried about aging and acne.

The user is seeking recommendations for a knowledgeable dermatologist in the Denver/Boulder area to address male pattern baldness, as they are dissatisfied with their current treatment of topical finasteride and are considering switching to dutasteride. They feel their current doctor is not open to exploring different treatments that could improve hairline thickness.

The user experienced severe side effects from finasteride, including panic attacks and suicidal thoughts, and is seeking alternative hair loss treatments. They have been using oral finasteride and topical minoxidil.

The user has been using pyrilutamide, topical finasteride, and 15% minoxidil for hair growth for almost 4 years. Despite mixed responses from others, the user reports seeing progress, especially with the addition of pyrilutamide, and plans to continue the regimen.

A user applied pyrilutamide for 6 months without hair regrowth and is considering stopping due to cost and lack of results. Another user suggests switching to finasteride, which is cheaper and has shown regrowth for them.

The conversation is about the potential side effects of using verteporfin in conjunction with a hair transplant. Specific treatments discussed include verteporfin, a hair transplant (HT), minoxidil (Min), finasteride (Fin), and RU58841 (RU).

A user on finasteride for 8 months shared bloodwork results showing increased testosterone and estradiol levels, with concerns about high LH. Responses advised monitoring for symptoms but noted levels are within reference ranges.

A user in the UAE is facing customs issues with ordering Fluridil (Eucapil) and is considering ordering smaller quantities or switching to Pyrilutamide. They are also using finasteride daily to maintain hair and are unsure of Fluridil's effectiveness.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

OP is pausing hair loss treatments to focus on mental health due to anxiety and side effects from RU58841. They plan to try topical finasteride and minoxidil after recovering from pneumonia.

DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

OP used minoxidil for 15 months and pyrilutamide for 46 days, achieving desired results without side effects. Users discussed alternatives like dutasteride and finasteride, with concerns about side effects like erectile dysfunction.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.